Bristol-Myers Squibb
4Q Revenues: $5.2 billion (+4%)
4Q Earnings: $1.2 billion (loss of $89 million in 4Q08)
FY Revenues: $20.6 billion (+13%)
FY Earnings: $5.2 billion (+142%)
Comments: Pharmaceutical sales were $4.5 billion in the quarter (+4%). U.S. pharmaceutical sales were up 13% to $2.8 billion, while international sales were down 9% to $1.7 billion, primarily due to an 8% unfavorable foreign exchange impact. Plavix sales were $1.5 billion (+7%). Pravachol sales were down 70% to $27 million due to generic competition. Baraclude sales were $153 million (+55%). Erbitux sales dropped 2% to $182 million. Sprycel sales were up 54% to $86 million and Ixempra sales were $25 million (+67%). Sustiva Franchise revenue was $300 million (+15%). Abilify sales were $606 million (+31%) and Orencia sales were up 72% to $129 million. R&D expenses were $1.1 billion (+29%). Earnings in the quarter include a $582 million after-tax gain related the sale of BMS' stake in ImClone Systems.
Magazine
